Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Diabetes Care 29:137-138, 2006
DOI: 10.2337/diacare.29.01.06.dc05-1270
© 2006 by the American Diabetes Association
This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Calafiore, R.
Right arrow Articles by Brunetti, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Calafiore, R.
Right arrow Articles by Brunetti, P.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Emerging Treatments and Technologies
Brief Report

Microencapsulated Pancreatic Islet Allografts Into Nonimmunosuppressed Patients With Type 1 Diabetes

First two cases

Riccardo Calafiore, MD1, Giuseppe Basta, MD1, Giovanni Luca, MD1, Angelo Lemmi, MD2, M. Pia Montanucci, PHD1, Giuseppe Calabrese, MD1, Leda Racanicchi, PHD1, Francesca Mancuso, PHD1 and Paolo Brunetti, MD1

1 Department of Internal Medicine, University of Perugia, Perugia, Italy
2 Department of Radiology and Imaging, University of Perugia, Perugia, Italy

Address correspondence and reprint requests to Riccardo Calafiore, MD, Department of Internal Medicine, University of Perugia, Via E. Dal Pozzo, 06126 Perugia, Italy. E-mail: islet{at}unipg.it

Abbreviations: OGTT, oral glucose tolerance test • sCPR, serum C-peptide response • TX, human islet allograft


   INTRODUCTION
TOP
 INTRODUCTION
RESEARCH DESIGN AND METHODS
 RESULTS
 CONCLUSIONS
 References
 
Time-related decline of human islet allograft (TX) function in generally immunosuppressed type 1 diabetic patients (1–5) has led us, after years of preclinical study (6), to initiate a phase 1 pilot clinical trial of microencapsulated TX into 10 nonimmunosuppressed patients with type 1 diabetes, under permission and surveillance by the Italian Ministry of Health (file no. 19382, PRE 805, 5 September 2003).


   RESEARCH DESIGN AND METHODS
TOP
 INTRODUCTION
 RESEARCH DESIGN AND METHODS
RESULTS
 CONCLUSIONS
 References
 
Human islet procurement
Human islets were isolated from single-donor pancreases according to the Edmonton protocol (1). Only preparations complying with standard quality control criteria (1) were considered for TX. The islets were cultured for 24 h in HAM F12 (Celbio, Milano, Italy), supplemented with antibiotics and 1.25% human albumin (Kedrion Spa, Milano, Italy) at 37°C in 95% air/CO2.

Microencapsulation
The islets were washed and thoroughly mixed with 1.6% endotoxin- and pyrogen-free sodium alginate (Stern Italia, Milan, Italy) that had been highly purified according to U.S. Pharmacopeia. Upon extrusion through a microdroplet generator (droplets generated by combination of air shears and mechanical pressure by a peristaltic pump), microdroplets containing the islets, upon collection in a CaCl2 bath, turned into gel microbeads. The beads, containing 1–2 islets and measuring an average 500 µm in diameter, were sequentially double-coated with 0.12% and 0.06% poly-L-ornithine (Sigma) and finally with 0.04% sodium alginate (Stern) (7).

Patient recruitment
Ten patients with long-standing type 1 diabetes on intensive insulin therapy regimens (lispro prebreakfast, lunch, and supper and glargine presupper) and undetectable serum C-peptide responses (sCPRs) were tested for complete blood chemistry, parameters of diabetes control (GHb, daily blood glucose profiles, and insulin requirement), anti–GAD 65 antibodies, and islet cell antibodies. Chest X-ray and abdominal echography were also performed.

Pre- and post-TX patient assessment
The patients were maintained on euglycemia overnight before TX by supplementing exogenous insulin as required. After TX, the patients were monitored hourly for blood glucose (range: 80–150 mg/dl) and insulin requirement. sCPR samples, assayed by radioimmunoassay (sCPR sensitivity: 0.06 ng/ml [intra-assay CV 3.7–4.5%, interassay CV 4.4–5%]) (TechnoGenetics, Milan, Italy) in our laboratory, were drawn twice daily for the first 7 days and weekly thereafter, both in basal and 90 min after meals. A 75-g oral glucose tolerance test (OGTT) was scheduled for patient 1 at 60 days post-TX. At 7 days post-TX, the patients were discharged and instructed to continue blood glucose home self-monitoring, with adjustments of insulin requirement. At 30 days post-TX, control abdominal echography was scheduled.

Encapsulated human islets for TX
A total of 400,000 and 600,000 microencapsulated islets (islet equivalents normalized to 150 µ) were grafted in patient 1 and patient 2, respectively. The final TX volume included 50 ml of microcapsules diluted in 100 ml of saline. Empty microcapsules did not exceed 5% of total.

Site of TX and delivery procedure.
At the Department of Radiology and Imaging, with the patients under local anesthesia (2% xylocaine) but no systemic sedation, the central abdominal region, under echography guidance, was punctured by a 14-gauge needle and therein injected with a few milliliters of saline to create a virtual space within the peritoneal leaflets for microcapsule delivery by a 60- ml plastic syringe over 15 min.


   RESULTS
TOP
 INTRODUCTION
 RESEARCH DESIGN AND METHODS
 RESULTS
CONCLUSIONS
 References
 
Both patients showed a rise in sCPR levels several weeks post-TX, amelioration of their mean daily blood glucose levels, and a progressive decline in exogenous insulin consumption. GHb also decreased throughout months of post-TX follow-up. At 60 days post-TX, an OGTT in patient 1 showed a biphasic C-peptide response, compatible with the presence of differentiated islet ß-cells. At 1 year (patient 1) and 6 months (patient 2) of post-TX follow-up, which is in progress, sCPR was still detected in these recipients (Table 1).


View this table:
[in this window]
[in a new window]
  		Table 1— Patients 1 and 2 pre- and post-TX

 

   CONCLUSIONS
TOP
 INTRODUCTION
 RESEARCH DESIGN AND METHODS
 RESULTS
 CONCLUSIONS
References
 
Our long-standing experimental background in the field has enabled us to initiate a pilot clinical trial of microencapsulated human islet TX into nonimmunosuppressed patients with type 1 diabetes. Current data seems to show that the TX procedure is simple, noninvasive, painless, and devoid of side effects. Although the patients were unable, thus far, to withdraw exogenous insulin, we believe that decline in GHb, disappearance (patient 1) of frequent weekly hypoglycemic episodes, and responsiveness to OGTT (patient 1) overall indicated TX metabolic function. Adjustments in grafted viable islet cell mass dosing might further improve clinical results in the remaining eight case subjects.


   Footnotes
 
A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C Section 1734 solely to indicate this fact.

Received for publication July 8, 2005. Accepted for publication September 17, 2005.


   References
TOP
 INTRODUCTION
 RESEARCH DESIGN AND METHODS
 RESULTS
 CONCLUSIONS
 References
 

  1. Ryan EA, Lakey JRT, Paty BW, Imes S, Korbutt GS, Kneteman NM, Bigam D, Rajotte RV, Shapiro AMJ: Successful islet transplantation: continued insulin reserve provides long-term glycemic control. Diabetes 51:2148–2157, 2002[Abstract/Free Full Text]
  2. Hering BJ, Kandaswamy R, Ansite JD, Eckman PM, Nakano M, Sawada T, Matsuomo I, Ihm S-H, Zhang HJ, Parkey J, Hunter DW, Sutherland DER: Single donor, marginal dose islet transplantation in patients with type 1 diabetes. JAMA 293:830–835, 2005[Abstract/Free Full Text]
  3. Goss JA, Goodpastor SE, Brunicardi FC, Soltes GD, Garber AJ, Hamilton DJ, Alejandro R, Ricordi C: Development of a human pancreatic islet transplant program through a collaborative relationship with a remote islet isolation center. Transplantation 77:462–466, 2004[Medline]
  4. Kessler L, Bucher P, Milliat-Guittard L, Benhamou PY, Soltes GD, Garber AJ, Badeet L, Thivelet C, Bayle F, Oberholzer J, Renoult E, Brun MJ, Rifle G, Atlan C, Colin C, Morel P, GRAGIL Group: Influence of islet transportation on pancreatic islet transplantation in type 1 diabetic patients with the Swiss-French network. Transplantation 77:1301–1304, 2004[Medline]
  5. Ryan EA, Paty BW, Senior PA, Bigam D, Alfadhli E, Kneteman NM, Lakey JRT, Shapiro AMJ: Five-year follow-up after clinical islet transplantation. Diabetes 54:2060–2069, 2005[Abstract/Free Full Text]
  6. Calafiore R, Basta G, Luca G, Calvitti M, Calabrese G, Racanicchi L, Macchiarulo G, Mancuso F, Guido L, Brunetti P: Grafts of microencapsulated pancreatic islet cells for the therapy of diabetes mellitus in nonimmunosuppressed animals. Biotechnol Applied Biochem 39:159–164, 2004
  7. Basta G, Sarchielli P, Luca G, Rcanicchi L, Nastruzzi C, Guido L, Mancuso F, Macchiarulo G, Calabrese G, Brunetti P, Calafiore R: Optimized parameters for microencapsulation of pancreatic islet cells: an in vitro study clueing on islet graft immunoprotection in type 1 diabetes mellitus. Transpl Immunol 13:289–296, 2004[Medline]

Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?



This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Calafiore, R.
Right arrow Articles by Brunetti, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Calafiore, R.
Right arrow Articles by Brunetti, P.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum